New & Events
Discover our latest news, blog posts and upcoming events.
We are thrilled to announce that ArtiQ has been acquired by Clario, a leading healthcare research and technology company renowned for its groundbreaking contributions to clinical evidence generation.
We are happy to announce our partnership with AstraZeneca, reflecting our shared dedication to advancing research on respiratory conditions and enhancing the quality of life for individuals with lung diseases.
This study shows that AI-based decision support on PFT interpretation improves accurate and early ILD diagnosis.
This study investigates the speed at which an expert can perform PFT interpretations.
This study investigates how the recently published ERS/ATS guidelines for lung function interpretation (Stanojevic 2021) affect patient classification compared to the previous document (Pellegrino 2005).
In this study, we are investigating the impact of instant feedback provided by an AI algorithm (ArtiQ.QC) on the quality of home spirometry.
This study explores the value and reliability of artificial intelligence (AI) based quality control software (ArtiQ.QC) to assess spirometry quality in clinical trials using the 2019 ATS/ERS guidelines.
AstraZeneca, a global pharmaceutical leader, has embarked on a transformative journey in clinical trials by integrating digital health solutions.
ArtiQ and AstraZeneca Belgium hosted Smart Spirometry webinar which explored the crucial role of spirometry in primary care, the impact of AI on workflow, and the potential for more accurate COPD diagnosis in high-risk patients.
Clario integrates AI into clinical trial data collection for spirometry with new partnership with ArtiQ
This study explores perspectives on spirometry provision in primary care, and the potential for AI decision-support software to aid quality and interpretation.
By focusing on a population at risk of COPD without a formal diagnosis, we study how ArtiQ.Spiro can support general practitioners (GPs) in diagnosing COPD.
This study gives insights into the prevailing ideas of Belgian GPs about the spirometry and identifies barriers and facilitators for its use in primary care.
This study evaluates the ability of AI to diagnose respiratory diseases in primary care on a representative dataset (UK Biobank, UKBB) using spirometry.
Artificiële Intelligentie helpt huisartsen longziekten opsporen
ArtiQ ranked in the CB Insights’ 2022 ‘Digital Health 150’ List
NuvoAir Partners with ArtiQ to Provide AI-Based Over-Reading of Spirometry to Improve Efficiency of Clinical Trials
This study with 19 pulmonologists and 60 retrospective cases shows an improvement in diagnostic accuracy of the primary diagnosis from 44% to 63%.
This study where 78 pulmonologists collaborated with ArtiQ.PFT on 24 PFT cases shows an increase in diagnostic accuracy of up to 10%.
AI detected ILD in 27% of subjects, 3.8±2.1 years prior to ILD diagnosis through standard care.